


WHAT IS CLAIMED IS:

1           1. An analgesic/anti-inflammatory pharmaceutical  
2 dosage form which comprises an effective amount of an active  
3 ingredient selected from the group consisting of racemic 5-  
4 benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, of the  
5 formula



6  
7  
8  
9  
10  
11  
12 optically active forms thereof and pharmaceutically acceptable  
13 salts thereof, in combination with a pharmaceutically  
14 acceptable excipient or diluent, said dosage form being an  
15 intranasally administrable dosage form.

1           2. The dosage form of claim 1 comprising 0.5-40 mg  
2 of said active ingredient.

1           3. The dosage form of claim 2 comprising 2-20 mg of  
2 said active ingredient.

1           4. The dosage form of claim 1 comprising 5-20% of  
2 said active ingredient (weight/volume).

1           5. The dosage form of claim 1 in a single-dose  
2 form.

1           6. The dosage form of claim 1 in the form of a  
2 solution or suspension.

1           7. The dosage form of claim 1 containing 15% of  
2 said active ingredient.

1           8. The dosage form of claim 1 wherein said  
2 excipient comprises a bioadhesive.

1           9. The dosage form of claim 1 wherein said  
2 excipient comprises a polymer that dissolves vehicle viscosity  
3 based on temperature change, to increase said viscosity at body  
4 temperature.

1           10. The dosage form of claim 1 further comprising as  
2 an excipient an intranasal absorption promoter.  
3

1           11. The dosage form of claim 10 wherein said  
2 promoter is selected from the group consisting of POE (9)  
3 lauryl alcohol and sodium glycocholate and lysophosphatidyl  
4 choline.  
5

1           12. A method for the treatment of inflammatory  
2 processes and pain of a traumatic or pathologic origin, which  
3 comprises the administration by the intranasal route of an  
4 effective amount of the active ingredient 5-benzoyl-2,3-  
5 dihydro-1H-pyrrolizine-1-carboxylic acid, in a racemic or  
6 optically active form or in the form of a pharmaceutically  
7 acceptable salt.

1           13. A method according to claim 8 wherein said  
2 effective amount is within the range of 0.5-40 mg.

1           14. A method according to claim 8 wherein said  
2 effective amount is within the range of 5-30 mg.

1           15. A method according to claim 8 wherein said  
2 effective amount is within the range of 5-20% (weight/volume).

1           16. A method according to claim 8 wherein said  
2 effective amount is within the range of 15% (weight/volume).

1           17. A method for the treatment of inflammatory  
2 processes and pain of a traumatic or pathologic origin which

3

11/11/11

[illegible]